Kymera Therapeutics (KYMR) Cash & Current Investments (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Cash & Current Investments data on file, last reported at $650.9 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $650.9 million, up 40.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $650.9 million (up 40.54% YoY), and the FY2025 annual result was $848.3 million, up 73.56% from the prior year.
• Cash & Current Investments eased to $650.9 million in Q1 2026 per KYMR's latest filing, from $848.3 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $848.3 million in Q4 2025 and troughed at $33.7 million in Q1 2022.
• A 5-year average of $452.9 million and a median of $481.9 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments slumped 89.89% in 2022, then surged 1076.52% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $407.2 million in 2022, then decreased by 7.93% to $374.9 million in 2023, then surged by 30.37% to $488.7 million in 2024, then soared by 73.56% to $848.3 million in 2025, then fell by 23.26% to $650.9 million in 2026.
• Business Quant data shows KYMR's Cash & Current Investments at $650.9 million in Q1 2026, $848.3 million in Q4 2025, and $505.7 million in Q3 2025.